The stock market is mixed on Tuesday, with the Dow Jones Industrial Average down 0.01%, the Nasdaq up 0.21% and the S&P up 0.51%. Tuesday’s winners include a telecommunications company who is near a deal with a larger firm and a pharmaceutical company whose drug received orphan status from the U.S. Food and Drug Administration. Meanwhile, the losers include another pharmaceutical company who discontinued a study on a lung-cancer drug and a retailer who cut its third-quarter outlook.
These are Tuesday’s market winners and losers.
Biggest Winners
Shares of MetroPCS Communications Inc. (NYSE: PCS) are up 18.19% to $13.61 on trading volume of 6.7 million shares. Bloomberg reported Tuesday that Deutsche Telekom AG is near some sort of deal with MetroPCS. Before Tuesday, the 52-week high was $12.48.
Shares of Cell Therapeutics Inc. (NASDAQ: CTIC) are up 17.49% to $2.62 on trading volume of 4 million shares. The FDA granted orphan status to its brain cancer drug, the company announced Tuesday. The 52-week high is $8.25.
Biggest Losers
Shares of ArQule Inc. (NASDAQ: ARQL) are down 55.41% to $2.23 on trading volume of 16 million shares. The company said it is discontinuing its late-stage study of a drug for lung-cancer patients since it has shown it won’t improve survival rates. Before Tuesday, the 52-week low was $4.46.
Shares of Express Inc. (NYSE: EXPR) fell 20.45% to $11.94 on trading volume of 4.8 million shares. The company cut its third-quarter profit outlook to between 16 cents and 20 cents a share, down from 27 cents to 32 cents a share. Before Tuesday, the 52-week low was $14.50.
Samuel Weigley
Follow him on Twitter: SWeigley
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.